CapMan’s Q3 results were below our and consensus expectations.
After the recent rights issue, Ascelia has SEK 95.
Redeye sees a Q3 report on the soft side from Transtema.
Redeye provides its initial take on Acarix’s Q3 report, which showed revenues falling short of estim...
Relais reported Q3 adjusted EBITA of EUR 9.2m, 9% below LSEG Data & Analytics consensus.
Redeye provides an initial take following the release of Optomed’s Q3 2024 report.
Redeye comments on Truecaller’s Q3 2024 report and the new CEO appointment.
Redeye provides an initial comment on the Q3 2024 report from Catella.
CapMan reported Q3 adjusted EBIT of EUR 2.0m, 23% below LSEG Data & Analytics consensus, most of whi...
Suominen's Q3 earnings fell significantly short of Vara Research consensus, mainly due to a EUR ~3m ...
Redeye provides an update following Neola Medical’s Q3 2024 report.
Redeyes view on the announced sizable order from a German operator.
Better than feared, sales still down 20% y-o-y, but margin held up well Near-term market and program...
Suominen’s revenue grew 5% y/y in Q3, which was below estimates.
Marimekko's third quarter revenue was in line with our estimates, yet profitability fell a tad short...
